Godolphin, P; Bath, P; Algra, A; Berge, E; Chalmers, J; Eliasziw, M; Hankey, G; ... Montgomery, A; + view all Godolphin, P; Bath, P; Algra, A; Berge, E; Chalmers, J; Eliasziw, M; Hankey, G; Hosomi, N; Ranta, A; Weimar, C; Woodhouse, L; Montgomery, A; - view fewer (2020) Cost-benefit of outcome adjudication in nine randomised stroke trials. Clinical Trials , 17 (5) pp. 576-580. 10.1177/1740774520939231.

Preview

Text Godolphin_AOST_Cost_manuscript_accepted version_04May20.pdf - Accepted Version Download (386kB) | Preview

Abstract

Background: Central adjudication of outcomes is common for randomised trials and should control for differential misclassification. However, few studies have estimated the cost of the adjudication process. Methods: We estimated the cost of adjudicating the primary outcome in nine randomised stroke trials (25,436 participants). The costs included adjudicators’ time, direct payments to adjudicators, and co-ordinating centre costs (e.g. uploading cranial scans and general set-up costs). The number of events corrected after adjudication was our measure of benefit. We calculated cost per corrected event for each trial and in total. Results: The primary outcome in all nine trials was either stroke or a composite that included stroke. In total, the adjudication process associated with this primary outcome cost in excess of £100,000 for a third of the trials (3/9). Mean cost per event corrected by adjudication was £2295.10 (SD: £1482.42). Conclusions: Central adjudication is a time-consuming and potentially costly process. These costs need to be considered when designing a trial and should be evaluated alongside the potential benefits adjudication brings to determine whether they outweigh this expense.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item